论文部分内容阅读
目的探讨阿托伐他汀联合阿司匹林治疗高血压伴动脉粥样硬化的临床疗效。方法选取福建省龙岩市第一医院2014年10月—2015年10月收治的高血压伴动脉粥样硬化患者78例,通过单双号分组法将所有患者分为对照组与研究组,每组39例。对照组患者予以阿司匹林治疗,研究组患者予以阿司匹林联合阿托伐他汀治疗,比较两组患者治疗前后血压(舒张压、收缩压)水平、血脂指标[三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]水平、治疗前后斑块面积变化情况及不良反应发生情况。结果治疗前两组患者舒张压、收缩压水平比较,差异无统计学意义(P>0.05);治疗后两组患者舒张压、收缩压水平均较治疗前改善,且研究组低于对照组(P<0.05)。治疗前两组患者TC、TG、LDL-C、HDL-C水平比较,差异有统计学意义(P>0.05);治疗后两组患者TC、TG、LDL-C、HDL-C水平均较治疗前改善,且研究组患者TC、TG、LDL-C水平低于对照组,HDL-C水平高于对照组(P<0.05)。治疗前及治疗6个月后,两组患者的斑块面积比较,差异无统计学意义(P<0.05);治疗12个月后,研究组患者的斑块面积小于治疗前及治疗6个月后,且小于对照组(P<0.05);两组患者均未见明显不良反应。结论阿司匹林联合阿托伐他汀治疗高血压伴动脉粥样硬化的临床疗效确切,可有效降低患者血压和血脂水平,且可减小动脉粥样硬化斑块面积。
Objective To investigate the clinical efficacy of atorvastatin combined with aspirin in the treatment of hypertension with atherosclerosis. Methods A total of 78 hypertensive patients with atherosclerosis were selected from the First Hospital of Longyan City, Fujian Province from October 2014 to October 2015. All patients were divided into control group and study group by single and double grouping method, and each group 39 cases. The patients in the control group were treated with aspirin. The patients in the study group were treated with aspirin combined with atorvastatin. The levels of blood pressure (diastolic blood pressure and systolic blood pressure), blood lipid (triglyceride (TG), total cholesterol (TC) , Low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)], changes of plaque area before and after treatment and incidence of adverse reactions. Results There were no significant differences in diastolic blood pressure and systolic blood pressure before treatment between the two groups (P> 0.05). After treatment, the diastolic blood pressure and systolic blood pressure of both groups improved compared with those before treatment, and the study group was lower than the control group P <0.05). The levels of TC, TG, LDL-C and HDL-C in the two groups before treatment were significantly different (P> 0.05). After treatment, TC, TG, LDL-C and HDL- The levels of TC, TG and LDL-C in the study group were lower than those in the control group, and the levels of HDL-C in the study group were higher than those in the control group (P <0.05). There were no significant differences in plaque area between the two groups before and 6 months after treatment (P <0.05). After 12 months of treatment, the plaque area in the study group was smaller than that before treatment and 6 months And less than the control group (P <0.05). No adverse reactions were observed in both groups. Conclusions Aspirin combined with atorvastatin is effective in treating hypertension with atherosclerosis, which can effectively reduce blood pressure and blood lipid levels and reduce the area of atherosclerotic plaque.